On the origin of p53 G:C → T:A transversions in lung cancers

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 508, Issue 1-2, 2002, Pages 1-19

  Rodin, Sergei N ^a   Rodin, Andrew S ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cell lines; p53 mutations; Repair; Tumorigenic selection

Indexed keywords

ADENINE; CARCINOGEN; CYTOSINE; GUANINE; MUTAGENIC AGENT; NITROGEN; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THYMINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CANCER RISK; CODON; CONTROLLED STUDY; DATA BASE; DNA REPAIR; DNA STRAND; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; MUTAGENESIS; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SMOKING;

ADENINE; CHI-SQUARE DISTRIBUTION; DATABASES, GENETIC; DNA REPAIR; GENE FREQUENCY; HUMANS; LUNG NEOPLASMS; MUTATION; POINT MUTATION; POLYCYCLIC HYDROCARBONS, AROMATIC; SMOKING; THYMINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037206612     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(02)00106-9     Document Type: Article

References (64)

1. Lopez A.D. Measuring the health hazards of tobacco: commentary. Bull. Who. 77:1999;82-83.
2. Cairns J. Mutation and cancer: the antecedents to our studies of adaptive mutation. Genetics. 148:1998;1433-1440.
3. Hecht S.S. Tobacco smoke carcinogens. J. Natl. Cancer Inst. 21:1999;1194-2010.
4. Ruggeri B., DiRado M., Zhang S.Y., Bauer B., Goodrow T., Klein-Szanto A.J. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G → T mutations in the p53 gene. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1013-1017.
5. Hainaut P., Pfeifer G.P. Patterns of p53 G → T transversions in lung cancers reflect the primary mutagenic signature of DNA damage by tobacco smoke. Carcinogenesis. 22:2001;367-374.
6. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in p53. Science. 274:1996;430-432.
7. Smith L.E., Denissenko M.F., Bennett W.P., Li H., Amin S., Tang M., Pfeifer G.P. Targeting of lung cancer mutational hot spots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst. 92:2000;803-811.
8. Rodin S.N., Rodin A.S. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc. Natl. Acad. Sci. U.S.A. 97:2000;12244-12249.
9. Rodin S.N., Rodin A.S. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11927-11932.
10. Denissenko M.F., Pao A., Pfeifer G.P., Tang M. Slow repair of bulky DNA adducts along the nontrancribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene. 16:1998;1241-1247.
11. Husgafvel-Pursiainen K., Boffetta P., Kannio A., Nyberg F., Pershagen G., Mukeria A., Constantinescu V., Fortes C., Benhamou S.S. p53 mutations and exposure to environmental tobacco smoke in a multicenter study of lung cancer. Cancer Res. 60:2000;2906-2911.
12. Vahakangas K.H., Bennett W.P., Castren K., Welsh J.A., Khan M.A., Blomeke B., Alavanja M.C.R., Harris C.C. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 61:2001;4350-4356.
13. Fujimoto H., Sasaki J.-C., Matsumoto M., Suga M., Ando Y., Iggo R., Tada M., Saya H., Ando M. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn. J. Cancer Res. 89:1998;696-702.
14. Wang X., Christiani D.C., Wiencke J.K., Fischbein M., Xu X., Cheng T.J., Mark E., Wain J.C., Kelsey K.T. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol., Biomarkers Prev. 4:1995;543-548.
15. Husgafvel-Pursiainen K., Karjalainen A., Kannio A., Anttila S., Partanen T., Ojajarvi A., Vainio H. Lung cancer and past occupational exposure to asbestos. Am. J. Respir. Cell Mol. Biol. 20:1999;667-674.
16. Rusin M., Butklewicz D., Matusecka E., Zborek A., Harasim J., Czyzewski K., Bennett W.P., Shields P.G., Weston A., Welsh J.A., Kryzowska-Gruca S., Chorazy M., Harris C.C. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. Br. J. Cancer. 80:1999;1445-1452.
17. Cote R.J., Jhanwar S.C., Novick S., Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 51:1991;5410-5416.
18. Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin K., Linnainman K., Tammilehto L., Mattson K., Gerwin B.I., Harris C.C. p53 and K-ras mutations in human mesothelioma cell lines. Cancer Res. 53:1992;2610-2615.
19. Hojo S., Fujita J., Yamadori I., Kamei T., Yoshinouchi T., Ohtsuki Y., Okada H., Bandoh S., Yamaji Y., Takahara J., Fukui T., Kinoshita M. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur. Respir. J. 12:1998;1404-1408.
20. Gao H.-G., Chen J.-K., Stewart J., Song B., Rayappa C., Whong W.-Z., Ong T. Distribution of p53 and K-ras mutations in human lung cancer tissues. Carcinogenesis. 18:1997;473-478.
21. Nernandez-Boussard T.M., Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ. Health Perspect. 106:1998;385-391.
22. Yngveson A., Williams C., Hjerpe A., Lundeberg J., Soderkvist P., Pershagen G. P53 mutations in lung cancer associated with residential radon exposure. Cancer Epidemiol. Biomarkers Prev. 8:1999;433-438.
23. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T., Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52:1992;734-736.
24. Takeshima Y., Seyama T., Bennett W.P., Akiyama M., Tokuoka S., Inai K., Mabuchi K., Land C.E., Harris C.C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 342:1993;1520-1521.
25. Isobe T., Hiyama K., Yoshida Y., Fujiwara Y., Yamakido M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res. 85:1994;1240-1246.
26. Lee I.N., Shew J.Y., Sheu J.C., Lee Y.C., Lee W.C., Fang M.T., Chang I.F., Yu C.J., Yang P.C., Luh K.T. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 150:1994;1667-1671.
27. Law J.C., Whiteside T.L., Gollin S.M., Weissfeld J., El-Ashmawy L., Srivastava S., Landreneau R.J., Johnson J.T., Ferrell R.E. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract. Clin. Cancer Res. 1:1995;63-768.
28. Takagi Y., Koo L.C., Osada H., Ueda R., Kyaw K., Ma C.-C., Suyama M., Saji S., Takahashi T., Tominaga S., Takahashi T. Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong. Cancer Res. 55:1995;5354-5357.
29. Lung M.L., Wong M.P., Skaanild M.T., Fok C.L., Lam W.K., Yew W.W. p53 mutations in non-small cell lung carcinomas in Hong Kong. Chest. 109:1996;718-726.
30. Takagi Y., Osada H., kuroishi T., Mitsudomi T., Kondo M., Niimi T., Saji S., Gazdar A.F., Takahashi T., Minna J.D., Takahashi T. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br. J. Cancer. 77:1998;1568-1572.
31. Huang C.L., Taki T., Adachi M., Konishi T., Higashiyama M., Kinoshita M., Hadama T., Miyake M. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancers. Int. J. Oncol. 12:1998;553-563.
32. Marchetti A., Pellegrini S., Sozzi G., Bertacca G., Gaeta P., Buttitta F., Carnicelli V., Griseri P., Chella A., Angeletti C.A., Pierotti M., Bevilacqua G. Genetic analysis of lung tumors of non-smoking status: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br. J. Cancer. 78:1998;73-78.
33. Miyake M., Adachi M., Huang C.-L., Higashiyama M., Kodama K., Taki T. A novel molecular staging protocol for non-small cell lung cancer. Oncogene. 18:1999;2397-2404.
34. Gealy R., Zhang L., Siegfried J.M., Luketich J.D., Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol. Biomarkers Prev. 8:1999;297-302.
35. Tokuchi Y., Hashimoto T., Kobayashi Y.Y., Hayashi M., Nishida K., Hayashi S., Imai K., Nakachi K., Ishikawa Y., Nakagawa K., Kawakami K., Tsuchiya E. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br. J. Cancer. 80:1999;1623-1629.
36. Rodin S.N., Holmquist G.P., Rodin A.S. CpG transition strand asymmetry and hitch-hiking mutations as measures of tumorigenic selection in shaping the p53 mutation spectrum. Int. J. Mol. Med. 1:1998;191-199.
37. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194:1987;391-396.
38. Tornaletti S., Pfeifer G.P. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene. 10:1995;1493-1499.
39. A.S. Yang, P.A. Jones, A. Shibata, The mutational burden of 5-methylcytosine, in: "Epigenetic Mechanisms of Gene Regulation", Cold Spring Harbor Lab. Press, Plainview, NY, pp. 77-94.
40. Loft S., Poulsen H.E. Cancer risk and oxidative DNA damage in man. J. Mol. Med. 74:1996;297-312.
41. Vahakangas K.H., Samet J.M., Metcalf R.A., Welsh J.A., Bennett W.P., Lane D.P., Harris C.C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 339:1992;576-580.
42. Wani M.A., Zhu Q., El-Mahdy M., Venkatachalam S., Wani A.A. Enhanced sensitivity to anti-benzo[a][yrene-diol-epoxide DNA damage correlates with decreased global genome repair attributable to abrogated p53 function in human cells. Cancer Res. 60:2000;2273-2280.
43. Klungland A., Rosewell I., Hollenbash S., Larsen E., Daly G., Epe B., Seeberg E., Lindahl T., Barnes D.E. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc. Natl. Acad. Sci. U.S.A. 96:1999;13300-13305.
44. Yokota A., Wada M., Shimosato Y., Terada M., Sugimura T. Loss of heterozygosity on chromosomes 3, 13, 17 in small cell carcinoma and on chromosome 3 in adnocarcinoma of the lung. Proc. Natl. Acad. Sci. U.S.A. 84:1987;9252-9256.
45. Lu R., Nash H.M., Verdine G.L. A mammalian DNA repair enzyme that excises oxidatively damaged guanines maps to a locus frequently lost in lung cancer. Curr. Biol. 7:1997;397-407.
46. Wistuba I.I., Bryant D., Behrens C., Milchgrub S., Virmani A.K., Ashfag R., Minna I.D., Gazdar A.F. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin. Cancer Res. 5:1999;991-1000.
47. Venit S., Biggs S.P.J. Radon, mycotoxins, p53, and uranium mining. Lancet. 343:1994;795.
48. Lo Y.M.D., Darby S., Noakes L., Whitley E., Silcocks P.B.S., Fleming K.A., Bell J.I. Screening for codon 249 p53 mutation in lung cancer associated with domestic radon exposure. Lancet. 345:1995;60.
49. Bartsch H., Hollstein M., Mustonen R., Schmidt J., Spiethoff A., Wesch H., Wiethege T., Muller K.-M. Screening for putative radon-specific p53 mutation hot spot in German uranium miners. Lancet. 346:1995;121.
50. Denissenko M.F., Koudriakova T.B., Smith L., O'Connor T.R., Riggs A.D., Pfeifer G.P. The p53 codon 249 mutational hot spot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene. 17:1998;3007-3014.
51. Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int. J. Oncol. 15:1999;927-934.
52. Strauss B.S. Role in tumorigenesis of silent mutations in the TP53 gene. Mutat. Res. 457:2000;93-104.
53. Krawczak M., Smith-Sorensen B., Schmidtke J., Kakkar V.V., Cooper D.N., Hovig E. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Human. Mut. 5:1995;48-57.
54. Tomlinson I.P., Novelli M.R., Bodmer W.F. The mutation rate and cancer. Proc. Natl. Acad. Sci. U.S.A. 93:1996;14800-14803.
55. Tomlinson I., Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat. Med. 5:1999;11-12.
56. Rubin H. Selected cell and selective microenvironment in neoplastic development. Cancer Res. 61:2001;799-807.
57. Rubin H. The role of selection in progressive neoplastic transformation. Adv. Cancer Res. 83:2001;159-207.
58. Rubin H. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. Carcinogenesis. 22:2001;1903-1930.
59. ARIC investigators, The atherosclerosis risk in communities (ARIC) study design and objectives, Am. J. Epidemiol. 129 (1989) 687-702.
60. Hussain S.P., Amstad P., Raja K., Sawyer M., Hofseth L., Shields P.G., Hewer A., Phillips D.H., Ryberg D., Haugen A., Harris C.C. Mutability of p53 hot spot codons to benzo[a]pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res. 61:2001;6350-6355.
61. Wei D.-J.C., Chang R.L., Bhachech N., Cui X.X., Merkler K.A., Wong C.-Q., Hennig E., Yagi H., Jerina D.M., Conney A.H. Doze-dependent differences in the profile of mutations induced by (+)-7R,8S-dyhydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo-(a)pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in chinese hamster V-79 cells. Cancer Res. 53:1993;3294-3301.
62. Wei S.-J.C., Chang R.L., Cui X.X., Merkler K.A., Wong C.-Q., Yagi H., Jerina D.M., Conney A.H. Dose-dependent differences in the mutational profiles of (-)-(1R,2S,3S,4R)-3,4-dihydroxy-1,2-epoxy-1,2,3,4- tetrahydrobenzo[c]phenanthrene and its less carcinogenic enantiomer. Cancer Res. 56:1996;3695-3703.
63. Hecht S.S. Metabolically activated carcinogens and mutations in the p53 tumor suppressor gene in lung cancer. J. Natl. Cancer Inst. 92:2000;782-783.
64. Zheng Y., Pao A., Adair G.N., Tang M.-S. Cyclobutane pyrimidine dimers and bulky chemical DNA adducts are efficiently repaired in both strands of either a transcriptionally active or promoter-deleted APRT gene. J. Biol. Chem. 276:2001;16786-16796.